The published record describes IGF-1 DES, written more precisely as des(1-3)IGF-1, as a naturally occurring truncated form of insulin-like growth factor 1 with its first three N-terminal residues removed. The structural edit is small and confined to the tip of the chain, yet it is what separates this molecule from its parent: the receptor-binding core is left almost untouched while affinity for the IGF binding proteins drops sharply. It remains an investigational research compound rather than an approved human therapeutic, and most of what the literature reports about it comes from cell and tissue models, not human clinical trials.
Removing the N-terminal Gly-Pro-Glu tripeptide from the 70-residue parent yields a 67-residue analog whose receptor-binding core is preserved but whose affinity for the IGF binding proteins is sharply reduced.
Every structural claim made about the DES variant is a statement about what changes relative to this 70-residue parent, so the literature treats the native architecture as the baseline reference. Mature human IGF-1 is a compact, single-chain molecule whose fold is pinned by three disulfide bridges into a proinsulin-like arrangement of domains.
Mature human IGF-1 is a 70-residue, roughly 7,649-dalton single chain locked by three disulfide bonds (Cys6-Cys48, Cys18-Cys61, Cys47-Cys52) into B, C, A, and D domains that echo the proinsulin blueprint.
The DES nomenclature is literal in the published usage: DES marks a deletion, and the parenthetical (1-3) names residues one through three as the ones removed. The change is subtractive at the very tip of the chain rather than a rearrangement of the scaffold, which is why the folded core survives the edit intact.
The DES(1-3) variant lacks glycine, proline, and glutamic acid at positions one through three, a Gly-Pro-Glu tripeptide sitting ahead of the first cysteine so none of the three stabilizing disulfide bonds is disturbed.
In normal circulation most IGF-1 is not free but held in complexes with a six-member family of binding proteins, with IGFBP-3 and the acid-labile subunit accounting for the largest reservoir. The N-terminal residues, including the glutamate at position three, sit within the surface those carriers recognize, so deleting Gly-Pro-Glu erodes part of that contact interface and reported affinity falls markedly.
| Property | Native IGF-1 | des(1-3)IGF-1 |
|---|---|---|
| IGFBP-3 affinity | High; primary carrier | ~Tens-fold to ~100-fold lower |
| Circulating state | Mostly bound in ternary complex | Largely free |
| Free fraction at receptor | Small | Substantially larger |
Removing the N-terminal tripeptide lowers des(1-3)IGF-1's affinity for IGFBP-3 by roughly tens-fold to a hundredfold, shifting the equilibrium so a much larger free fraction is available to reach receptors.
The literature frames the potency gap as an availability effect, not a change in intrinsic signaling strength. Binding proteins act as a buffering system that ties up IGF-1 and releases it slowly; a peptide that escapes that buffering has more of itself free to act, and the size of the reported advantage tracks how much binding-protein buffering the model contains.
The apparent potency advantage of des(1-3)IGF-1, often several-fold to roughly ten-fold in cell-proliferation and protein-synthesis assays, comes from binding-protein escape and collapses in systems that contain no IGF binding proteins.
At the receptor the two peptides are far more alike than the potency data alone might suggest, because IGF-1 docks into the type 1 receptor mainly through its B and A domains rather than the first three residues the DES variant loses. The structural edit is close to invisible to the receptor and visible almost entirely to the binding proteins, which is what makes the molecule a clean tool for separating receptor activation from binding-protein control.
des(1-3)IGF-1 binds and activates the type 1 IGF receptor at an affinity close to native IGF-1, triggering the same PI3K and MAPK cascades, so the deletion is read almost entirely by the binding proteins rather than the receptor.
Des(1-3)IGF-1 is a genuinely endogenous species rather than a laboratory invention, generated in living tissue by a limited N-terminal cleavage that removes the Gly-Pro-Glu tripeptide and releases the free GPE fragment. Because the products are recoverable from fresh biological material, the truncated form is regarded as a real physiological variant, though careful handling is still needed to separate authentic truncation from proteolysis that can occur during extraction.
des(1-3)IGF-1 is an endogenous variant first isolated from bovine colostrum and generated in tissue by limited N-terminal proteolysis that removes the Gly-Pro-Glu tripeptide, with truncated forms enriched in colostrum and neural tissue.
For research quantities the peptide is generally produced recombinantly rather than harvested from tissue, and the central technical difficulty is oxidative folding into the correct disulfide pairing. The end product is documented as a research-grade material for laboratory investigation, not a formulated or approved human therapeutic.
Research-grade des(1-3)IGF-1 is generally made by expressing the 67-residue sequence recombinantly and refolding it under controlled redox conditions, then confirmed by mass spectrometry and reversed-phase chromatography, and it is supplied strictly as a research material rather than an approved human therapeutic.
Educational use only. This article describes what the published scientific and clinical literature reports about IGF-1 DES. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
